Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Abstract
Objective
To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in patients with multiple sclerosis (MS).Methods
This retrospective cohort study included anti-JC virus antibody-positive patients (n = 35,521) in the TOUCH database as of June...Paper Details
Title
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Published Date
Oct 8, 2019
Journal
Volume
93
Issue
15
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History